Financial updates Myosin Therapeutics Successfully Transitions to Second Phase of NCI’s Fast Track Funding to Advance MT-125 Jupiter, FL – [January 16, 2024] – After milestone review by the NIH’s National Cancer... January 16, 2024
Financial updates Myosin Therapeutics Closes Seed Round to Continue Development of Innovative Therapies for Glioblastoma and Stimulant Use Disorder Jupiter, FL – [March 7th, 2023] – Myosin Therapeutics Inc., a biotechnology company leveraging its... March 07, 2023
